E Parisi, D Arpa, G Ghigi, L Fabbri, F Foca, L Tontini, E Neri, M Pieri, S Cima, S Micheletti, R N Abousiam, M A Burgio, V Tonelli, M L Belli, L Luzzi, A Romeo
PURPOSE/OBJECTIVE(S): Malignant Pleural Mesothelioma (MPM) is a rare but aggressive intrathoracic malignancy with an overall poor prognosis. Neoadjuvant chemotherapy, surgery and then radiotherapy is the standard of care in early-stage disease. Our study aim is to evaluate the feasibility and toxicity of the novel adjuvant RT in accelerated hypofractionation. We report the lung toxicity preliminary results of the first patients entreated. MATERIALS/METHODS: Starting in 2017, 29 MPM patients were enrolled in the trial (IRST trial 163)...
October 1, 2023: International Journal of Radiation Oncology, Biology, Physics